Get the Stockscreener App
149.28
2.25%
3.29
Pre-market:
148.79
-0.49
-0.33%
Charles River Laboratories International Inc stock is traded at $149.28, with a volume of 1.19M.
It is up +2.25% in the last 24 hours and down -9.70% over the past month.
See More
Previous Close:
$145.99
Open:
$143.97
24h Volume:
1.19M
Relative Volume:
1.13
Market Cap:
$7.47B
Revenue:
$4.06B
Net Income/Loss:
$413.08M
P/E Ratio:
18.64
EPS:
8.01
Net Cash Flow:
$560.48M
1W Performance:
-5.67%
1M Performance:
-9.70%
6M Performance:
-22.61%
1Y Performance:
-42.98%
1-Day Range:
$142.76
$150.16
1-Week Range:
$142.76
$159.08
52-Week Range:
$142.76
$264.70
Charles River Laboratories International Inc Stock (CRL) Company Profile
Name
Charles River Laboratories International Inc
Sector
Industry
Phone
781-222-6000
Address
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
149.28 | 7.47B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
489.06 | 182.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.16 | 143.37B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
426.25 | 33.92B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
115.99 | 33.08B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
174.37 | 30.19B | 15.41B | 1.37B | 2.11B | 7.50 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-04-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-03-25 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Jan-22-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-17-25 | Downgrade | UBS | Buy → Neutral |
| Nov-18-24 | Downgrade | CLSA | Hold → Underperform |
| Nov-07-24 | Upgrade | CLSA | Underperform → Hold |
| Oct-23-24 | Initiated | CLSA | Underperform |
| Oct-14-24 | Initiated | Redburn Atlantic | Sell |
| Oct-07-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-01-24 | Downgrade | Citigroup | Neutral → Sell |
| Aug-08-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-08-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Downgrade | Argus | Buy → Hold |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-13-23 | Initiated | TD Cowen | Market Perform |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-12-23 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-04-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-24-22 | Initiated | Guggenheim | Neutral |
| Apr-25-22 | Downgrade | Jefferies | Buy → Hold |
| Apr-07-22 | Initiated | Stephens | Overweight |
| Feb-17-22 | Reiterated | BofA Securities | Buy |
| Feb-17-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-22 | Reiterated | Deutsche Bank | Buy |
| Feb-17-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-17-22 | Reiterated | UBS | Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Sep-10-20 | Upgrade | Jefferies | Hold → Buy |
| Jul-01-20 | Upgrade | BofA Securities | Neutral → Buy |
| May-13-20 | Upgrade | UBS | Neutral → Buy |
| Apr-21-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Feb-18-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-10-20 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-18-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-10-19 | Initiated | SVB Leerink | Outperform |
| Apr-30-19 | Resumed | Evercore ISI | Outperform |
| Dec-14-18 | Initiated | Deutsche Bank | Buy |
| Oct-09-18 | Initiated | UBS | Neutral |
| Aug-23-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-17-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-15-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Feb-14-18 | Upgrade | SunTrust | Hold → Buy |
View All
Charles River Laboratories International Inc Stock (CRL) Latest News
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
How Is Charles River Laboratories' Stock Performance Compared to Other Health Care Stocks? - Nasdaq
Charles River Integrates Akron Bio’s CSS Line of Liquid Cytokines - Contract Pharma
Charles River Labs stock hits 52-week low at $150.19 By Investing.com - Investing.com Australia
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN
Baird Adjusts Charles River Laboratories International Price Target to $155 From $173, Maintains Neutral Rating - MarketScreener
Charles River Labs stock hits 52-week low at $150.19 - Investing.com
Mawer Investment Management Ltd. Buys 5,769 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Genetic Toxicology Testing Market To Witness Huge Gains Over - openPR
Biopharma Layoffs Roundup - Contract Pharma
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform - BioSpace
Charles River, Valo Health Identify First Lupus Treatment Candidate Using Logica AI Platform - Marketscreener.com
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica - Business Wire
Why Charles River Laboratories International, Inc. (CRL) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Goldman Sachs Downgrades Charles River Laboratories International (CRL) - MSN
Demystifying Charles River: Insights From 10 Analyst Reviews - Benzinga
Icon stock, Charles River stock downgraded at Goldman (CRL) - Seeking Alpha
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga India
Goldman Sachs cuts Charles River Labs stock rating, target to $170 - Investing.com India
Goldman Sachs cuts Charles River Labs stock rating, target to $170 By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Charles River Laboratories International to Neutral From Buy, Adjusts Price Target to $170 From $190 - Marketscreener.com
Jefferies maintains Charles River Labs stock hold, price target at $169 - Investing.com Canada
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Interesting CRL Put And Call Options For November 21st - Nasdaq
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo Finance
Earnings call transcript: Charles River Labs beats Q4 2024 forecasts By Investing.com - Investing.com UK
Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$171? - Simply Wall St
Charles River Laboratories to Present at Barclays Global Healthcare Conference - BioSpace
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.
Mutual of America Capital Management LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Smartleaf Asset Management LLC Increases Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility - MSN
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN
Charles River, LabCorp upgraded, Quest downgraded at Citi on valuation - MSN
Charles River announces agreement with Singapore General Hospital - SelectScience
Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Citigroup - Defense World
Reasons to Retain Charles River Stock in Your Portfolio for Now - Yahoo Finance
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Charles River Laboratories Shares Rise After Citigroup Upgrade -March 04, 2025 at 02:53 pm EST - Marketscreener.com
Citi raises Charles River stock rating, lifts target to $175 - Investing.com
Citi raises Charles River stock rating, lifts target to $175 By Investing.com - Investing.com South Africa
Citigroup Upgrades Charles River Laboratories International to Neutral From Sell, Adjusts Price Target to $175 From $155 - Marketscreener.com
FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility - Joplin Globe
Charles River Laboratories International Inc Stock (CRL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
1.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):